1887
  1. Home
  2. Eurosurveillance
  3. Volume 29, Issue 38, 19/Sep/2024
  4. Article
Research Open Access
Like 0
Download

SDG 3: HIV/AIDS

Abstract

Background

In the Netherlands, HIV pre-exposure prophylaxis (PrEP) has been available since 2019. However, the extent of PrEP use prior to HIV diagnosis and development of PrEP-resistance-associated mutations (RAMs) is not known.

Aim

We assessed prior PrEP use and potential transmission of PrEP RAMs among men who have sex with men (MSM) and transgender persons (TGP) with a new HIV diagnosis in the Netherlands.

Methods

Data on prior PrEP use between 1 January 2018 and 31 December 2022 were available from the Dutch national ATHENA cohort. We assessed proportion of prior PrEP use, detected PrEP associated RAMs and assessed potential onward transmission of RAMs between 2010 and 2022 using a maximum likelihood tree.

Results

Data on prior PrEP use were available for 583/1,552 (36.3%) individuals, with 16% (94/583) reporting prior PrEP use. In 489 individuals reporting no prior PrEP use, 51.5% did not use PrEP due to: low HIV-risk perception (29%), no access (19.1%), personal preference (13.1%), and being unaware of PrEP (19.1%). For PrEP users, 13/94 (13.8%) harboured a M184V/I mutation, of whom two also harboured a K65R mutation. In people with a recent HIV infection, detection of PrEP RAMs increased from 0.23% (2/862) before 2019 to 4.11% (9/219) from 2019. We found no evidence of onward transmission of PrEP RAMs.

Conclusion

The prevalence of PrEP-associated RAMs has increased since PrEP became available in the Netherlands. More widespread access to PrEP and retaining people in PrEP programmes when still at substantial risk is crucial to preventing new HIV infections.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.38.2400083
2024-09-19
2024-09-26
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2024.29.38.2400083
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/38/eurosurv-29-38-5.html?itemId=/content/10.2807/1560-7917.ES.2024.29.38.2400083&mimeType=html&fmt=ahah

References

  1. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973-83.  https://doi.org/10.1097/QAD.0000000000001145  PMID: 27149090 
  2. Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015;373(23):2237-46.  https://doi.org/10.1056/NEJMoa1506273  PMID: 26624850 
  3. Girometti N, McCormack S, Tittle V, McOwan A, Whitlock G, 56 Dean Street Collaborative Group. Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes. AIDS. 2022;36(4):561-6.  https://doi.org/10.1097/QAD.0000000000003143  PMID: 34873084 
  4. Parikh UM, Mellors JW. How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention? Curr Opin HIV AIDS. 2022;17(4):213-21.  https://doi.org/10.1097/COH.0000000000000746  PMID: 35762376 
  5. Koole JC, de la Court F, Welkers MR, Yap K, Stalenhoef JE, Jurriaans S, et al. HIV-1-infection in a man who has sex with men despite self-reported excellent adherence to pre-exposure prophylaxis, the Netherlands, August 2021: be alert to emtricitabine/tenofovir-resistant strain transmission. Euro Surveill. 2022;27(14):2200275.  https://doi.org/10.2807/1560-7917.ES.2022.27.14.2200275  PMID: 35393931 
  6. Cohen SE, Sachdev D, Lee SA, Scheer S, Bacon O, Chen M-J, et al. Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV. 2019;6(1):e43-50.  https://doi.org/10.1016/S2352-3018(18)30288-1  PMID: 30503324 
  7. Knox DC, Anderson PL, Harrigan PR, Tan DHS. Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis. N Engl J Med. 2017;376(5):501-2.  https://doi.org/10.1056/NEJMc1611639  PMID: 28146652 
  8. Markowitz M, Grossman H, Anderson PL, Grant R, Gandhi M, Horng H, et al. Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. J Acquir Immune Defic Syndr. 2017;76(4):e104-6.  https://doi.org/10.1097/QAI.0000000000001534  PMID: 29076941 
  9. Ambrosioni J, Petit E, Liegeon G, Laguno M, Miró JM. Primary HIV-1 infection in users of pre-exposure prophylaxis. Lancet HIV. 2021;8(3):e166-74.  https://doi.org/10.1016/S2352-3018(20)30271-X  PMID: 33316212 
  10. Hoornenborg E, Achterbergh RC, van der Loeff MFS, Davidovich U, van der Helm JJ, Hogewoning A, et al. Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam. J Int AIDS Soc. 2018;21(3):e25105.  https://doi.org/10.1002/jia2.25105  PMID: 29603900 
  11. Boender TS, Smit C, Sighem AV, Bezemer D, Ester CJ, Zaheri S, et al. AIDS Therapy Evaluation in the Netherlands (ATHENA) national observational HIV cohort: cohort profile. BMJ Open. 2018;8(9):e022516.  https://doi.org/10.1136/bmjopen-2018-022516  PMID: 30249631 
  12. Bezemer D, Jurriaans S, Prins M, van der Hoek L, Prins JM, de Wolf F, et al. Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS. 2004;18(11):1571-7.  https://doi.org/10.1097/01.aids.0000131357.52457.33  PMID: 15238775 
  13. Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, Günthard HF, Paredes R, et al. 2022 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2022;30(4):559-74. PMID: 36375130 
  14. Price MN, Dehal PS, Arkin AP. FastTree: computing large minimum evolution trees with profiles instead of a distance matrix. Mol Biol Evol. 2009;26(7):1641-50.  https://doi.org/10.1093/molbev/msp077  PMID: 19377059 
  15. Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees for large alignments. PLoS One. 2010;5(3):e9490.  https://doi.org/10.1371/journal.pone.0009490  PMID: 20224823 
  16. Prosperi MCF, Ciccozzi M, Fanti I, Saladini F, Pecorari M, Borghi V, et al. A novel methodology for large-scale phylogeny partition. Nat Commun. 2011;2(1):321.  https://doi.org/10.1038/ncomms1325  PMID: 21610724 
  17. Kosakovsky Pond SL, Weaver S, Leigh Brown AJ, Wertheim JO. HIV-TRACE (TRAnsmission Cluster Engine): a Tool for Large Scale Molecular Epidemiology of HIV-1 and Other Rapidly Evolving Pathogens. Mol Biol Evol. 2018;35(7):1812-9.  https://doi.org/10.1093/molbev/msy016  PMID: 29401317 
  18. Kasaie P, Pennington J, Shah MS, Berry SA, German D, Flynn CP, et al. The Impact of Preexposure Prophylaxis Among Men Who Have Sex With Men: An Individual-Based Model. J Acquir Immune Defic Syndr. 2017;75(2):175-83.  https://doi.org/10.1097/QAI.0000000000001354  PMID: 28498144 
  19. Punyacharoensin N, Edmunds WJ, De Angelis D, Delpech V, Hart G, Elford J, et al. Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: a mathematical modelling study. Lancet HIV. 2016;3(2):e94-104.  https://doi.org/10.1016/S2352-3018(15)00056-9  PMID: 26847231 
  20. Reitsema M, Hoek AJV, van der Loeff MS, Hoornenborg E, van Sighem A, Wallinga J, et al. Preexposure prophylaxis for men who have sex with men in the Netherlands: impact on HIV and Neisseria gonorrhoeae transmission and cost-effectiveness. AIDS. 2020;34(4):621-30.  https://doi.org/10.1097/QAD.0000000000002469  PMID: 31895142 
  21. Grulich AE, Guy R, Amin J, Jin F, Selvey C, Holden J, et al. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV. 2018;5(11):e629-37.  https://doi.org/10.1016/S2352-3018(18)30215-7  PMID: 30343026 
  22. Grulich AE, Jin F, Bavinton BR, Yeung B, Hammoud MA, Amin J, et al. Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study. Lancet HIV. 2021;8(8):e486-94.  https://doi.org/10.1016/S2352-3018(21)00074-6  PMID: 34217426 
  23. Zhang J, Li C, Xu J, Hu Z, Rutstein SE, Tucker JD, et al. Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. Lancet HIV. 2022;9(4):e254-68.  https://doi.org/10.1016/S2352-3018(22)00030-3  PMID: 35364026 
  24. National Institute for Public Health and the Environment (RIVM). Sexually transmitted infections in the Netherlands in 2022. RIVM report 2023-0161. Bilthoven: RIVM; 2023. Available from: https://www.rivm.nl/bibliotheek/rapporten/2023-0161.pdf
  25. Sullivan AK, Saunders J, Desai M, Cartier A, Mitchell HD, Jaffer S, et al. HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment. Lancet HIV. 2023;10(12):e790-806.  https://doi.org/10.1016/S2352-3018(23)00256-4  PMID: 38040478 
  26. Traeger MW, Schroeder SE, Wright EJ, Hellard ME, Cornelisse VJ, Doyle JS, et al. Effects of Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who Have Sex With Men: A Systematic Review and Meta-analysis. Clin Infect Dis. 2018;67(5):676-86.  https://doi.org/10.1093/cid/ciy182  PMID: 29509889 
  27. Vuylsteke B, Reyniers T, De Baetselier I, Nöstlinger C, Crucitti T, Buyze J, et al. Daily and event-driven pre-exposure prophylaxis for men who have sex with men in Belgium: results of a prospective cohort measuring adherence, sexual behaviour and STI incidence. J Int AIDS Soc. 2019;22(10):e25407.  https://doi.org/10.1002/jia2.25407  PMID: 31663257 
  28. Hoornenborg E, Coyer L, Achterbergh RCA, Matser A, Schim van der Loeff MF, Boyd A, et al. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study. Lancet HIV. 2019;6(7):e447-55.  https://doi.org/10.1016/S2352-3018(19)30136-5  PMID: 31178284 
  29. Holt M, Lea T, Mao L, Kolstee J, Zablotska I, Duck T, et al. Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17. Lancet HIV. 2018;5(8):e448-56.  https://doi.org/10.1016/S2352-3018(18)30072-9  PMID: 29885813 
  30. van Bilsen WPH, Boyd A, van der Loeff MFS, Davidovich U, Hogewoning A, van der Hoek L, et al. Diverging trends in incidence of HIV versus other sexually transmitted infections in HIV-negative MSM in Amsterdam. AIDS. 2020;34(2):301-9.  https://doi.org/10.1097/QAD.0000000000002417  PMID: 31714354 
  31. Frost SDW, Nijhuis M, Schuurman R, Boucher CAB, Brown AJL. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol. 2000;74(14):6262-8.  https://doi.org/10.1128/JVI.74.14.6262-6268.2000  PMID: 10864635 
  32. Misra K, Huang JS, Udeagu C-CN, Forgione L, Xia Q, Torian LV. Preexposure Prophylaxis Use History in People With Antiretroviral Resistance at Human Immunodeficiency Virus (HIV) Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015-2022. Clin Infect Dis. 2024;78(5):1240-5.  https://doi.org/10.1093/cid/ciad699  PMID: 37976185 
  33. de la Court F, Boyd A, Coyer L, van den Elshout M, de Vries HJC, Matser A, et al. The impact of COVID-19-related restrictions in 2020 on sexual healthcare use, pre-exposure prophylaxis use, and sexually transmitted infection incidence among men who have sex with men in Amsterdam, the Netherlands. HIV Med. 2023;24(2):212-23.  https://doi.org/10.1111/hiv.13374  PMID: 36226479 
  34. Gouy M, Tannier E, Comte N, Parsons DP. Seaview Version 5: A Multiplatform Software for Multiple Sequence Alignment, Molecular Phylogenetic Analyses, and Tree Reconciliation. In: Katoh K. (eds) Multiple Sequence Alignment. Methods in Molecular Biology, vol 2231. Humana, New York. 2021.  https://doi.org/10.1007/978-1-0716-1036-7_15  https://doi.org/10.1007/978-1-0716-1036-7_15 
Oral HIV pre-exposure prophylaxis use and resistance-associated mutations among men who have sex with men and transgender persons newly diagnosed with HIV in the Netherlands: results from the ATHENA cohort, 2018 to 2022
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Vita+W+Jongen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Jongen Vita W</a>, <a href="/search?value1=Daniela+Bezemer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bezemer Daniela</a>, <a href="/search?value1=Ard+van+Sighem&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van Sighem Ard</a>, <a href="/search?value1=Anders+Boyd&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Boyd Anders</a>, <a href="/search?value1=Casper+Rokx&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rokx Casper</a>, <a href="/search?value1=Karin+Grintjes&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Grintjes Karin</a>, <a href="/search?value1=Aafke+Cents-Bosma&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cents-Bosma Aafke</a>, <a href="/search?value1=Eline+Op+de+Coul&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Op de Coul Eline</a>, <a href="/search?value1=Birgit+van+Benthem&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van Benthem Birgit</a>, <a href="/search?value1=Annemarie+Wensing&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wensing Annemarie</a>, <a href="/search?value1=Ferdinand+WNM+Wit&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wit Ferdinand WNM</a>, <a href="/search?value1=Marc+van+der+Valk&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van der Valk Marc</a>, <a href="/search?value1=on+behalf+of+the+ATHENA+national+observational+HIV+cohort&option1=author&noRedirect=true" class="nonDisambigAuthorLink">on behalf of the ATHENA national observational HIV cohort</a></span>. Oral HIV pre-exposure prophylaxis use and resistance-associated mutations among men who have sex with men and transgender persons newly diagnosed with HIV in the Netherlands: results from the ATHENA cohort, 2018 to 2022. <a href="/content/ecdc">Euro Surveill.</a> 2024;29(38):pii=2400083. <a href="https://doi.org/10.2807/1560-7917.ES.2024.29.38.2400083" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2024.29.38.2400083</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 06 Feb 2024;&nbsp;&nbsp; <span class="generated">Accepted</span>: 07 Jun 2024 </span> </p>
/content/10.2807/1560-7917.ES.2024.29.38.2400083
/content/10.2807/1560-7917.ES.2024.29.38.2400083
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error